Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS

By sjmartinez • May 8, 2025

DeZern AE, Thepot S, De Botton S, Patriarca A, Deeren D, Torregrose Diaz JM, Marconi G, Bernal Del Castillo T, Bergua Burgues JM, Xicoy B, Jonasova A, Zeidan AM, Dimicoli-Salazar S, Simand C, Valcárcel D, Díez-Campelo M, Chai-Ho W, Saini L, Garnier A, Geissler K, Ofran Y, Nagy Z, Krishnamurthy P, Lübbert M, Basak GW, Carraway HE, Sallman DA, Borate U, Santini V, Campbell V, Fenaux P, Braun T, Lanza F, Zaucha JM, Roth DA, Paul S, Roy P, Kelly M, Volkert A, Chisolm J, Abdul Malak T, Klimek V, Cluzeau T. Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS. Blood Adv. 2025 May 7:bloodadvances.2025016229. doi: 10.1182/bloodadvances.2025016229. Epub ahead of print. PMID: 40334070.

Tags: Hematology/Oncology, Publications

Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON

Peters S, Oliner KS, L'Hernault A, Ratcliffe M, Madison H, Lai Z, Stewart R, Mann H, Lowery C, Garon EB, Mok T, Johnson ML. Durvalumab[...]

Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement

Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar[...]

Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study

Özgüroğlu M, Goldman JW, Chen Y, Garassino MC, Medic N, Mann H, Chugh P, Dalvi T, Paz-Ares L. Adverse events self-reported by patients with extensive-stage[...]